Abstract:Abstract Background Most studies examining differences in gut microbiota composition between healthy individuals and inflammatory bowel disease (IBD) patients, have been conducted on patients receiving immunosuppressive therapy. Such treatments can modify the gut microbiome and skew research data. The IBDomics cohort is a unique population of newly diagnosed IBD patients. Our aim was to elucidate the microbiota in this cohort compared to healthy controls (HC), and the differences between patients with Crohn’s disease (CD) and ulcerative colitis (UC). Methods Stool samples were collected from 104 patients with CD, 145 patients with UC, within the 1st month after the diagnosis (prior to any IBD treatment), and 49 HC. Patients were classified according to endoscopic activity, using the Simple Endoscopic Score for CD (SES-CD) and the endoscopic subscore of the Mayo index for UC. Shotgun metagenomic sequencing was used to analyze microbiota composition. Shannon index (α-diversity) and Bray-Curtis dissimilarity (β-diversity) were used as tests of within-species diversity and within-group diversity, respectively. Results CD patients had a statistically significant decrease in α-diversity, compared to UC and HC; in addition, an inverse relationship was observed between the severity of CD activity and microbial α-diversity. On the opposite, the UC severity had no impact on α-diversity. β-diversity between pair-wise combinations was reduced in UC vs. HC compared to CD vs. HC. This index increased directly with severity in CD patients, while there was no difference in UC patients based on endoscopic severity (Figure 1). Considering the microbial taxonomic abundance, the greatest differences in UC patients compared to HC were found in Toxoplasma gondii and Gemella morbillorum. Of these two species, the 1st showed a direct relationship with the severity of activity and the 2nd one decreased with disease severity. CD patients had the greatest differences in several species of Adlercreutzia and Shigella genus compared to HC (Table 1). Upon grouping CD patients by disease activity, Adlercreutzia hattorii exhibited a consistent decrease across all activity subgroups compared to HC, while Shigella flexneri displayed a significant increase in CD activity groups without notable variance among them. This suggests that the presence of these bacteria is more closely associated with the intrinsic pathology of CD rather than its severity. Conclusion Newly diagnosed CD patients showed notable differences in microbiota compared to UC patients and HC. However, UC microbiome is relatively close to HC. Most of the species detected in the abundance analysis contribute to dysbiosis: declining beneficial genus like Gemella and Adlercreutzia and enhancing pathogen species.

DOP26 Metagenomic and metabolomic profiles in IBD: understanding microbial and metabolic shifts from a large deeply phenotyped cohort

Gut microbiome structure and metabolic activity in inflammatory bowel disease

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment

Gut microbiota signatures in inflammatory bowel disease

Faecal metabolome and its determinants in inflammatory bowel disease

Inferring intestinal mucosal immune cell associated microbiome species and microbiota-derived metabolites in inflammatory bowel disease

Metabolic modeling reveals a multi-level deregulation of host-microbiome metabolic networks in IBD

Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets

The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease

Microbiome and Metabolome Features in Inflammatory Bowel Disease Via Multi-Omics Integration Analyses Across Cohorts

P1230 Integrated analysis of microbiome and metabolome reveals disease-specific profiles in inflammatory bowel disease and intestinal Behcet’s disease

DOP33 Distinct perturbances in metabolic pathways associate with disease progression in patients with Inflammatory Bowel Disease

Systematic Mining of gut microbiota biomarkers for IBD

P010 Faecal microbiota composition by shotgun metagenomic sequencing approach in a newly diagnosed cohort of inflammatory bowel disease patients: results from the IBDomics project

P140 Serum Metabolomic Biomarkers Can Identify and Characterize Associated Subtypes and Phenotypes in Inflammatory Bowel Disease

Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases

Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease

P033 Unrevealing new potential key mechanisms implicated in inflammatory bowel disease by multiomic approach

Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases

P324 Urine metabolite profile characterizes clinical activity and disease extent in patients with inflammatory bowel disease